Cytokine-Mediated

Human Beta Cell Inflammation Assay

Cytokine-Mediated

Human Beta Cell Inflammation Assay

REVEALING YOUR DRUG POTENTIAL USING A HUMAN PATHOLOGICALLY RELEVANT TYPE 1 AND TYPE 2 DIABETES-MEDIATED INFLAMMATION ASSAY

Evaluate the anti-inflammatory and beta cell protection potential of your drug compounds

Inflammation is a major and complex component of pathogenic processes in type 1 and type 2 diabetes mellitus. In type 1 diabetes, inflammation is a primary event that persists and intensifies as the disease progresses, whereas in type 2 diabetes, inflammation is a chronic feature. In both types of diabetes, the phenomenon involves inflammatory cytokines and is responsible for impaired insulin secretion and the destruction of pancreatic beta cells, making it a central strategy for drug discovery activities targeting Diabetes. Using Endoc-BH5® cells, this assay reproduces the clinically observed response of human pancreatic beta cells to cytokine-induced inflammation. It enables you to assess the pharmacological efficacy of your drug discovery strategies aiming to modulate inflammatory response and protect beta cells from inflammation.

REVEALING YOUR DRUG POTENTIAL USING A HUMAN PATHOLOGICALLY RELEVANT TYPE 1 AND TYPE 2 DIABETES-MEDIATED INFLAMMATION ASSAY

Evaluate the anti-inflammatory and beta cell protection potential of your drug compounds

Inflammation is a major and complex component of pathogenic processes in type 1 and type 2 diabetes mellitus. In type 1 diabetes, inflammation is a primary event that persists and intensifies as the disease progresses, whereas in type 2 diabetes, inflammation is a chronic feature. In both types of diabetes, the phenomenon involves inflammatory cytokines and is responsible for impaired insulin secretion and the destruction of pancreatic beta cells, making it a central strategy for drug discovery activities targeting Diabetes. Using Endoc-BH5® cells, this assay reproduces the clinically observed response of human pancreatic beta cells to cytokine-induced inflammation. It enables you to assess the pharmacological efficacy of your drug discovery strategies aiming to modulate inflammatory response and protect beta cells from inflammation.

FEATURES AND BENEFITS

A unique humanized and pharmacologically validated assay

Recapitulates in vitro the cytokine-mediated inflammation process of type 2 and type 1 diabetes

Human Assay
Pathophysiologically relevant
Screen and profile your compounds at all stages from early inflammation-induced cell dysfunction to apoptosis
Acute and chronic treatment compatible (>3 weeks)
Assess cell protection
Combine functional readout with death and inflammation readouts
HTS compatible

A unique humanized and pharmacologically validated assay

Recapitulates in vitro the cytokine-mediated inflammation process of type 2 and type 1 diabetes

Human Assay
Pathophysiologically relevant
Screen and profile your compounds at all stages from early inflammation-induced cell dysfunction to apoptosis
Acute and chronic treatment compatible (>3 weeks)
Assess cell protection
Combine functional readout with death and inflammation readouts
HTS compatible

ASSAY CONCEPT

schema-inflammation-assay-2160px

ASSAY CONCEPT

APPLICATIONS

Anti-inflammatory potential
Beta cell protection
Screening campaigns
Specific target validation
Mechanism of action description

READOUT

Cell function decrease (Insulin secretion)
Cell viability & death
Cell inflammation profile
Beta cell identity markers
Functional markers
Mechanistic markers
Gene expression profile

HAVE A PROJECT IN MIND?

Human Cell Design team of experts can offer you tailored assays and EndoC-βH5® derived cell models.